{
    "2018-04-23": [
        [
            {
                "time": "2018-04-20",
                "original_text": "Johnson & Johnson’s Revenues Continued to Rise in 1Q18",
                "features": {
                    "keywords": [
                        "revenues",
                        "rise",
                        "1Q18"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-23",
                "original_text": "Drug/Biotech Stock Q1 Earnings Due on Apr 24: LLY, BIIB, AMGN",
                "features": {
                    "keywords": [
                        "earnings",
                        "due",
                        "LLY",
                        "BIIB",
                        "AMGN"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-21",
                "original_text": "Johnson & Johnson's Top-Line Growth Isn't What It Seems",
                "features": {
                    "keywords": [
                        "top-line",
                        "growth",
                        "seems"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-04-22",
                "original_text": "Analysts’ Estimates for Eli Lilly & Co.’s 1Q18 Earnings",
                "features": {
                    "keywords": [
                        "analysts",
                        "estimates",
                        "1Q18",
                        "earnings"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-21",
                "original_text": "Johnson & Johnson's Top-Line Growth Isn't What It Seems",
                "features": {
                    "keywords": [
                        "top-line",
                        "growth",
                        "seems"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-04-25",
                "original_text": "Geron Corporation: The Clock Is Ticking",
                "features": {
                    "keywords": [
                        "geron",
                        "corporation",
                        "clock",
                        "ticking"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-04-26",
                "original_text": "Why GlaxoSmithKline’s 1Q18 Revenues Are Expected to Fall",
                "features": {
                    "keywords": [
                        "glaxosmithkline",
                        "revenues",
                        "expected",
                        "fall"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-04-27",
                "original_text": "Merck’s Relebactam Met Primary Endpoints in Phase 3 Study",
                "features": {
                    "keywords": [
                        "merck",
                        "relebactam",
                        "met",
                        "primary",
                        "endpoints",
                        "phase",
                        "3",
                        "study"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-28",
                "original_text": "British businesses embrace profits with a purpose",
                "features": {
                    "keywords": [
                        "british",
                        "businesses",
                        "embrace",
                        "profits",
                        "purpose"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "business"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}